STING1 and neoplasm: Due to the roles of TLR and STING signaling in immune responses such as tumor antigen presentation, T cell recruiting chemokines secretion within the tumor, and inflammation within the tumor microenvironment that supports cytotoxic immune cell function, many TLR and STING agonists have been developed to serve as vaccine adjuvants or cancer immunotherapeutics [15].